ADMA Biologics Inc (ADMA)

Financial leverage ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Total assets	US$ in thousands	488,678	390,618	376,399	350,875	329,182	348,997	343,027	340,788	348,461	300,558	296,932	308,032	276,253	238,640	232,814	235,667	207,673	189,976	191,542	210,524
Total stockholders’ equity	US$ in thousands	349,018	231,890	188,269	153,706	135,206	151,437	146,762	145,655	151,974	100,385	114,401	126,933	141,173	102,780	111,594	112,504	88,249	71,376	76,879	96,336
Financial leverage ratio		1.40	1.68	2.00	2.28	2.43	2.30	2.34	2.34	2.29	2.99	2.60	2.43	1.96	2.32	2.09	2.09	2.35	2.66	2.49	2.19

December 31, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $488,678K ÷ $349,018K
= 1.40

The financial leverage ratio measures the extent to which a company relies on debt to finance its operations and growth. ADMA Biologics Inc's financial leverage ratio has fluctuated over the past few years, starting at 2.19 on March 31, 2020, peaking at 2.99 on September 30, 2022, and declining to 1.40 on December 31, 2024.

A higher financial leverage ratio indicates a higher level of debt relative to equity, suggesting higher financial risk. Conversely, a lower ratio implies a lower reliance on debt financing and potentially lower financial risk.

The trend in ADMA Biologics Inc's financial leverage ratio indicates fluctuating levels of debt usage over time. It peaked in September 2022 and has since decreased by the end of 2024. This could suggest a shift in the company's financing strategy or a focus on reducing debt levels. It is essential for stakeholders to monitor these fluctuations to assess the company's risk profile and financial stability.